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Abstract
Background: The exact diagnosis of double primary papillary adenocarcinoma of thyroid and lung is even rarer, to
our knowledge no report in the literature by [
18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography/X-ray
CT(FDG PET/CT) with surgical specimens immunohistochemistry(IHC). We report a patient with abnormal FDG PET/
CT in thyroid and lung, this unusual presentation may lead to misdiagnosis without surgical specimens IHC.
Case presentation: A 56-year-old man with coughing three months. FDG PET/CT was performed, and resection
specimens of lung and thyroid were detected by hematoxylin eosin staining (HE) and IHC. PET/CT: lung tumor
SUVmax: 3.69, delay: 5.17; and thyroid tumor SUVmax 19.97. HE reveal papillary adenocarcinoma, but histological
differentiation of primary pulmonary adenocarcinoma from metastatic adenocarcinoma is sometimes difficult
because of their phenotypic similarities. So IHC was performed, the IHC of lung tumor: cytokeratin 20 (CK20)(-),
thyroglobulin(Tg)(-), cytokeratin7(CK7)(+), thyroid transcription factor-1 (TTF-1)(+); thyroid tumor: CK7(+), TTF-1(+),
thyroglobulin (+), CK20(-). Therefore, the final diagnosis was double primary adenocarcinomas of thyroid and lung.
Conclusion: FDG PET/CT has preliminary diagnostic capacity of multiple primary tumors; the final diagnosis should
be adopted for specimens after tumor-specific markers IHC to obtain. Consequently, effective therapeutic
approaches can be designed and conducted.
Background
Early detection and correct diagnosis are essential for
definite treatment and better outcome of cancer
patients. FDG PET/CT scans can detect thyroid inciden-
talomas of which 33.2%-63.6% are found with malignant
phenotypes, and a body of evidences has shown the
effectiveness of PET/CT in differential diagnosis of
benign and malignant tumors [1-3]. Nevertheless, it
remains difficult to distinguish multiple primary tumors
from the metastatic ones with this approach and, there-
fore, fine-needle aspiration (FNA) and cytological exami-
nation have to be employed in the final diagnosis.
Malhotra G et al [4] found bronchoalveolar carcinoma
of lung masquerading as iodine avid metastasis in a
patient with minimally invasive follicular thyroid cancer.
However, their conclusion just only based on the IHC
of CT-guided biopsy, and the diagnostic accuracy of
core biopsy is lower than surgical excision specimen.
Eloy JA et al [1] reported that incidental FDG uptake in
the thyroid gland of the patients with nonthyroidal can-
cers was associated with a 27.8% risk for well-differen-
tiated thyroid carcinoma, but they did not provide
technical detail about differential diagnosis of multiple
primary tumours or metastatic diseases. The current
tumor classification is largely based on HE histological
staining, but the lining cells in pulmonary papillary ade-
nocarcinomas show cuboidal to columnar phenotypes,
an outlook similar to the papillary carcinoma of the
thyroid. In such case, IHC, in addition to conventional
histopathological examination, would be required to dis-
tinguish primary and metastatic adenocarcinomas from
the double primary cancers derived from different cells
but in similar phenotypes.
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We report a 56-year-old man who had suffered from
cough, chest tightness and shortness of breath for 3
months and became more aggravated for recent 3
weeks, without hoarseness or loss of voice, haemoptysis,
weight loss, bone pain, abdominal pain, the history of
thyroid disease and neurological symptoms. X-ray CT
examination detected a nodule in the right mid lobe of
the lung in the maximal diameter of 2.21 cm and irregu-
lar density, complementing with pleural retraction. The
CT value of this nodule was 42HU, the contrast
enhancement CT value was 70HU and the delayed one
was 81HU. Since the location of this nodule was beyond
the reach of fiberbronchoscopy forceps for cytological
examination and clinical staging, FDG PET/CT (GE Dis-
covery ST, USA) was performed, which showed the
increased FDG uptake of the tumor in terms of the
SUVmax in 3.69 and the delay SUV in 5.17 (Figure 1A
and 1B), and no abnormal FDG uptake was found in the
nodule-free lung tissues and mediastinum space. It was
also found that in the right lobe of the thyroid, there
was a round hypermetabolic focus in 1 cm maximal
flow path diameter, which showed FDG uptake of SUV-
max in 19.97, low CT density and ambiguity of the
Figure 1 Whole-body FDG PET/CT and radioiodine scan. A hypermetabolic focus in the mid lobe of lower lobe of the right lung with
increased FDG uptake in SUV max 3.69 (A) and delayed SUV 5.17 (B). PET/CT-detected round hypermetabolic focus in the right lobe of the
thyroid with abnormal FDG uptake in SUVmax 19.97(C). Postoperative therapeutic dose
131I whole body imaging showed mild accumulation of
radioiodine (T/NT 3.64) in the residuary thyroid, while no abnormal
131I uptake in the other side (D).
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l i z e da n ds u b j e c t e dt oar i g h tl u n gm i dl o b el o b e c t o m y
and mediastinal lymph node dissection. According to
the pathological examination, the surgical specimen was
elastic-firm and composed of the tumor cells that
arranged in papillary configuration or fused glandular
structures with irregularly enlarged hyperchromatic
nuclei (Figure 2). All of the six dissected mediastinal
lymph nodes were free of tumor cells. This specimen
was thus diagnosed as a well-differentiated pulmonary
adenocarcinoma without lymph node metastasis.
After the operation, the patient was treated by con-
ventional adjuvant chemotherapy with paclitaxel, cispla-
tin and vinorelbine tartrate for 4 cycles/courses. Six
months later, this patient was re-admitted for right lobe
thyroidectomy. The microscopic examination revealed a
papillary structure of the removed thyroid tissues with a
ground-glass appearance of tumor cell nuclei, irregular
nuclear contours and some colloid within neoplastic fol-
licles (Figure 2). Based on these pathological findings,
the removed specimen was diagnosed as papillary carci-
noma of the thyroid.
Sensitive and reliable markers such as TTF-1, Tg, CK7
and CK20 were used to further ascertain the origin(s) of
the two tumors co-existing in the lung and the thyroid.
TTF-1 and Tg are considered as markers for differential
diagnosis in distinguishing primary tumor of the thyroid
or lung from other origins. CK7 and CK20 are high
molecular weight cytokeratins, the different expression
patterns of CKs allow the accurate and sophisticated
classification of epithelial cells and their neoplasms into
different subtypes. So the IHC staining for TTF-1,
CK20, CK7 and Tg were performed on the two tumor
specimens(Figure 2), which revealed negative immunor-
eactivity of CK20, Tg but positive of CK7, TTF-1 in the
tumor removed from the lung; while positive immunor-
eactivity of CK7, TTF-1, Tg but negative of CK20 in the
tumor removed from the thyroid. These results sug-
gested that this patient bear double primary adenocarci-
nomas originated from the lung and the thyroid,
respectively. Three months after the second operation, a
therapeutic dose of
131I (100mCi) was adopted for abla-
tion thyroid remnant; 7 days later, the scintigraphy
showed mild accumulation of radioiodine (target/non-
target ratio: T/NT 3.64) in the residuary thyroid, while
no abnormal
131I uptake was found (Figure 1D). The
patient was followed up for 3 years. Comprehensive
examination revealed no sign of recurrence and metasta-
sis and the general physical state of the patient is well
kept.
Discussion
The diagnostic sensitivity and specificity of FDG PET/
CT scan has been fully validated in cancers. But with a
multiple abnormal FDG PET/CT scan, it is hard to
make a definite differential diagnosis of primary or
metastatic ones, and CT also can not distinguish pri-
mary tumors from metastatic ones, for example, solitary
pulmonary metastases similar to primary lung tumor. So
a multiple abnormal FDG PET/CT should lead to reeva-
luation of the initial diagnosis if the patient with a high
risk for secondary neoplasia. In this case, FDG PET/CT
scan detects two nodules in lung and the thyroid,
respectively, but can not make a final diagnosis about
concomitant pulmonary and thyroid tumors or meta-
static ones. Therefore, the following possibilities could
Figure 2 HE histological staining of the resected lung (L) and thyroid tumor tissue (T): The lining cells in resected lung tumor tissue
were cuboidal to columnar, similar to the papillary carcinoma of the thyroid. IHC staining: negative immunoreactivity of CK20 and
thyroglobulin but positive of CK7 and TTF-1 in the lung tumor; positive immunoreactivities of CK7, TTF-1 and thyroglobulin but not CK20 were
found in the thyroid tumor.
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priate approaches.
The possibility of lung adenocarcinomas (L-ACs) with
thyroid metastases was considered firstly. The L-ACs
are one of the most frequent malignancies, which have
strong tendency of distant metastasis via lymphatic or
hematogenous routes. The thyroid gland is a common
target organ of metastasis because of its rich vasculariza-
tion structure, and majority of the secondary thyroid
tumors are originated from the carcinomas of the breast
(8.8%), the stomach (7.7%) and especially the lungs
(43%) [5]. Histological differentiation of primary thyroid
cancers from metastatic L-ACs is sometimes difficult
because of their phenotypic similarities. L-ACs usually
exhibit cytoplasmic immunoreactivity of CK7 and nega-
tive CK20, while primary thyroid carcinomas show thyr-
oglobulin production [6]. In this case, the diagnosis of
L-ACs with thyroid metastasis can not be established
because of the positive immunolabeling of CK7, TTF-1
and Tg in the thyroid specimen.
Another possible diagnosis of this case was the thyroid
adenocarcinoma(T-AC)with lung metastases. As a
malignant epithelial tumor in the synonym of papillary
adenocarcinoma, T-ACs usually spread to regional
lymph nodes and, sometimes, form metastatic foci and
nodules in other organs including the lungs [7]. The
lung metastases from thyroid cancer are positive in thyr-
oglobulin, while this protein is negative either in pri-
mary lung cancers or in the tumors originated from
other sites [6]. In this case,s i n c et h et u m or specimen
removed from the lung was negative in CK20 and Tg
but positive in CK7 and TTF-1, it can be diagnosed as
primary adenocarcinoma of the lung rather than lung
metastasis from thyroid cancer.
Synchronous metastases to the lungs and the thyroid
can be found in clinic. FDG PET/CT can provide valu-
able information to establish this diagnosis by showing
other tumor(s) in addition to the nodules in the thyroid
and lungs. In this case, since no tumor was detected
besides lung and thyroid nodules via FDG PET/CT
scan, the possibility of synchronous metastases to the
lungs and the thyroid could be ruled out.
If with synchronous metastases, it is usually difficult to
determine the tissue origin of metastatic adenocarci-
noma simply based on their histopathological features.
In such case, IHC using specific biomarkers for indivi-
dual cancers would be informative in identifying tumor
origins. For example, TTF-1 and surfactant proteins
(SP-A, pro-SP-B, pro-SP-C) can be used to identify lung
cancer, thyroglobulin to thyroid, prostate specific anti-
gen to prostate, mammaglobin 1 to breast, pepsinogen
C to stomach, metallothionein IL to pancreas, uroplakin
II to bladder, MUC II to colon cancers [8].
Concomitant pulmonary and thyroid primary adeno-
carcinomas or multiple raised from different organs are
also possible such as the double adenocarcinomas of the
lungs and thyroid [9]. The incidences of multiple pri-
mary malignancies were about 11% and 7% among the
patients with overall and resected non-small cell lung
carcinomas [10]. In this case, based on the findings of
FDG PET/CT and IHC staining, double primary cancers
are highly speculated and finally determined, and more
definite remedies were thus designed for the primary
lung and thyroid adenocarcinomas of the patient, which
achieved desirable therapeutic results in terms of can-
cer-free status for 3 years.
To our knowledge, this is the first report of a patient
who was diagnosed with concomitant pulmonary and
thyroid primary adenocarcinomas by FDG PET/CT and
IHC approaches. Using ‘’double primary papillary adeno-
carcinoma of lung and thyroid’’ as keywords, the
PubMed Database yielded one similar case, but the diag-
nosis of that report didn’t based on IHC approaches,
only by HE.
Conclusion
FDG PET/CT has preliminary diagnostic capacity of
multiple primary tumors. The final diagnosis, only with
the surgical specimens, can be made based on the com-
bination of histological evaluation and IHC for the bio-
markers specific to individual tissue or cancer types.
Consequently, effective therapeutic approaches can be
designed and conducted.
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